Regulatory T cell therapy for uveitis

New therapeutic strategies, including novel generation of immunosuppressors and biologic agents are currently available for the management of noninfectious uveitis. However, adverse events remain an important issue to consider and other options need to be evaluated. We have previously controlled experimental autoimmune uveoretinitis by administrating activated polyclonal regulatory T cells (T‐regs) intravitreally. Based on these preliminaru results, a clinical study has been initiated to evaluate the safety and efficacy of this approach in patients with uveitis and low vision. Tolerance and efficacy will be monitored with clinical examination, laser flare photometry and imaging. Intraocular levels of pro and anti‐inflammatory cytokines will be determined in each patient at baseline and after T‐reg administration. Cell therapy may become an interesting strategy, expanding the anti‐inflammatory armamentarium.